Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Gastric Cancer Market, by Route of Administration
1.4.2 North America Gastric Cancer Market, by Treatment Type
1.4.3 North America Gastric Cancer Market, by Disease Type
1.4.4 North America Gastric Cancer Market, by Distribution Channel
1.4.5 North America Gastric Cancer Market, by Drug Class
1.4.6 North America Gastric Cancer Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Approvals & Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. North America Gastric Cancer Market by Route of Administration
4.1 North America Injectable Market by Country
4.2 North America Oral Market by Country
Chapter 5. North America Gastric Cancer Market by Treatment Type
5.1 North America Chemotherapy Market by Country
5.2 North America Targeted Therapy Market by Country
5.3 North America Immunotherapy Market by Country
5.4 North America Radiation Therapy & Surgery Market by Country
Chapter 6. North America Gastric Cancer Market by Disease Type
6.1 North America Adenocarcinoma Market by Country
6.2 North America Carcinoid Tumor Market by Country
6.3 North America Gastrointestinal Stromal Tumor Market by Country
6.4 North America Lymphoma Market by Country
6.5 North America Others Market by Country
Chapter 7. North America Gastric Cancer Market by Distribution Channel
7.1 North America Specialty & Retail Pharmacies Market by Country
7.2 North America Hospital Pharmacies Market by Country
7.3 North America Others Market by Country
Chapter 8. North America Gastric Cancer Market by Drug Class
8.1 North America PD-1/PD-L1 Inhibitors Market by Country
8.2 North America HER2 Antagonists Market by Country
8.3 North America VEGFR2 Antagonists Market by Country
8.4 North America Others Market by Country
Chapter 9. North America Gastric Cancer Market by Country
9.1 US Gastric Cancer Market
9.1.1 US Gastric Cancer Market by Route of Administration
9.1.2 US Gastric Cancer Market by Treatment Type
9.1.3 US Gastric Cancer Market by Disease Type
9.1.4 US Gastric Cancer Market by Distribution Channel
9.1.5 US Gastric Cancer Market by Drug Class
9.2 Canada Gastric Cancer Market
9.2.1 Canada Gastric Cancer Market by Route of Administration
9.2.2 Canada Gastric Cancer Market by Treatment Type
9.2.3 Canada Gastric Cancer Market by Disease Type
9.2.4 Canada Gastric Cancer Market by Distribution Channel
9.2.5 Canada Gastric Cancer Market by Drug Class
9.3 Mexico Gastric Cancer Market
9.3.1 Mexico Gastric Cancer Market by Route of Administration
9.3.2 Mexico Gastric Cancer Market by Treatment Type
9.3.3 Mexico Gastric Cancer Market by Disease Type
9.3.4 Mexico Gastric Cancer Market by Distribution Channel
9.3.5 Mexico Gastric Cancer Market by Drug Class
9.4 Rest of North America Gastric Cancer Market
9.4.1 Rest of North America Gastric Cancer Market by Route of Administration
9.4.2 Rest of North America Gastric Cancer Market by Treatment Type
9.4.3 Rest of North America Gastric Cancer Market by Disease Type
9.4.4 Rest of North America Gastric Cancer Market by Distribution Channel
9.4.5 Rest of North America Gastric Cancer Market by Drug Class
Chapter 10. Company Profiles
10.1 Novartis AG
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expense
10.1.5 Recent strategies and developments:
10.1.5.1 Partnerships, Collaborations, and Agreements:
10.2 Pfizer, Inc.
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional & Segmental Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Partnerships, Collaborations, and Agreements:
10.3 Viatris, Inc. (Mylan N.V.)
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Segmental Analysis
10.3.4 Research & Development Expense
10.3.5 Recent strategies and developments:
10.3.5.1 Product Launches and Product Expansions:
10.3.5.2 Approvals & Trials:
10.4 F. Hoffmann-La Roche Ltd.
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Partnerships, Collaborations, and Agreements:
10.4.5.2 Product Launches and Product Expansions:
10.5 Eli Lilly And Company
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Regional Analysis
10.5.4 Research & Development Expenses
10.5.5 Recent strategies and developments:
10.5.5.1 Approvals & Trials:
10.5.5.2 Partnerships, Collaborations, and Agreements:
10.6 Merck & Co., Inc.
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expenses
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.7 Teva Pharmaceutical Industries Ltd.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Regional Analysis
10.7.4 Research & Development Expenses
10.7.5 Recent strategies and developments:
10.7.5.1 Product Launches and Product Expansions:
10.7.5.2 Approvals & Trials:
10.7.5.3 Partnerships, Collaborations, and Agreements:
10.8 Bristol Myers Squibb Company
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 Recent strategies and developments:
10.8.5.1 Partnerships, Collaborations, and Agreements:
10.8.5.2 Approvals & Trials:
10.9 Celltrion Healthcare Co., Ltd.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Recent strategies and developments:
10.9.3.1 Partnerships, Collaborations, and Agreements:
10.10. Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.)
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Segmental and Regional Analysis
10.10.4 Research & Development Expenses
10.10.5 Recent strategies and developments:
10.10.5.1 Approvals & Trials:
10.10.5.2 Product Launches and Product Expansions:
Unique Offerings 